To know the trends in patent filing in India in the field of probiotics, a detailed search was performed at the official website for the granted patents and the published applications. Presented here is the summary of the trends.
Applying & Filing Patents in Medical Device Sector. We draft description of patents and complete patent specifications in accordance with the latest patent law. We help Patenting your Invention, Idea, & Innovation worldwide. We also perform Patent Validity Search & Patent Invalidity Searches for your technology.
This document provides interim guidelines for sharing biological and clinical samples and data related to COVID-19 research in India. It outlines procedures for acquiring, storing, and sharing samples and data while protecting individual privacy. Sample and data sharing can help accelerate COVID-19 research, but must be done safely and ethically in accordance with various regulatory frameworks. The guidelines establish a process for requesting and approving the sharing of samples and data between approved research institutions and stakeholders.
Case analysis novartis vs union of indiaMohit Bajaj
Novartis challenged the rejection of its patent application for the cancer drug Gleevec in India. The Madras Patent Office rejected the application on the grounds that Gleevec was merely a new salt form of the existing drug imatinib, and did not demonstrate enhanced efficacy as required by Section 3(d) of India's Patents Act. Novartis filed a legal challenge arguing that Section 3(d) violated international trade agreements and India's constitution. The court upheld Section 3(d) as compliant with trade rules and not arbitrary, finding that salt forms with modest improvements did not meet the standard of invention required for patents. The court also found it had jurisdiction to review compliance of domestic laws with international treaties.
This document discusses several patent cases in India between foreign pharmaceutical companies and Indian generic drug manufacturers. It summarizes key patent cases such as Novartis vs. India regarding Glivec, Bayer vs. Natco regarding Nexavar, Roche vs. Cipla regarding Tarceva. It also discusses India's patent laws including sections 3(d) and compulsory licensing. Many foreign drug patents were revoked by Indian courts based on lack of innovation or in the interest of public health and making medicines more affordable in India. The document supports India's stance on promoting generic competition and ensuring access to healthcare.
The document summarizes two key patent cases in India - Novartis AG's plea seeking patent protection for its cancer drug Glivec, which was dismissed, and Natco Pharma's compulsory license application for the cancer drug Nexavar, which was granted. The Novartis ruling confirmed that slight modifications alone do not warrant patents under Indian law. The Nexavar ruling allowed Natco to sell cheaper copies of Nexavar, requiring it to pay Bayer royalties and supply some free doses annually. These rulings make life-saving drugs more affordable in India by allowing generics, though multinational companies argue they could reduce pharmaceutical investment and innovation.
The document provides an overview of pharmaceutical patenting in India. It discusses key topics such as the role of intellectual property rights (IPRs) like patents, trademarks, and trade secrets in the pharmaceutical industry. It also examines India's pharmaceutical industry evolution from pre-independence to present. Specific issues covered include requirements for patentability, types of pharmaceutical patents, Section 3(d) of the Indian Patents Act, evergreening practices, compulsory licensing provisions, and mail box applications. The document uses examples like the Novartis case related to Gleevec and Natco Pharma's compulsory license for Bayer's anti-cancer drug Nexavar to illustrate relevant legal concepts and issues in Indian pharmaceutical patenting.
Ip protected invention in the field of biotechnologyKaran Veer Singh
This document discusses patenting of microorganisms, recombinant DNA, plant processes, gene patents, and applications of DNA sequences in India. Key points:
1) Isolated, mutated, adapted, and recombinant microorganisms can be patented under Indian law, and must be deposited in an IDA with disclosed source and geography.
2) Recombinant DNA techniques allow for patenting of processes, products, microorganisms and their variants, and proteins.
3) Plant processes involving increasing yield, genetic transformation, tissue culture, micropropagation, and somatic embryogenesis are patentable.
4) Gene patents can claim DNA sequences, proteins, recombinant plasmids, GM organisms, and production processes
Applying & Filing Patents in Medical Device Sector. We draft description of patents and complete patent specifications in accordance with the latest patent law. We help Patenting your Invention, Idea, & Innovation worldwide. We also perform Patent Validity Search & Patent Invalidity Searches for your technology.
This document provides interim guidelines for sharing biological and clinical samples and data related to COVID-19 research in India. It outlines procedures for acquiring, storing, and sharing samples and data while protecting individual privacy. Sample and data sharing can help accelerate COVID-19 research, but must be done safely and ethically in accordance with various regulatory frameworks. The guidelines establish a process for requesting and approving the sharing of samples and data between approved research institutions and stakeholders.
Case analysis novartis vs union of indiaMohit Bajaj
Novartis challenged the rejection of its patent application for the cancer drug Gleevec in India. The Madras Patent Office rejected the application on the grounds that Gleevec was merely a new salt form of the existing drug imatinib, and did not demonstrate enhanced efficacy as required by Section 3(d) of India's Patents Act. Novartis filed a legal challenge arguing that Section 3(d) violated international trade agreements and India's constitution. The court upheld Section 3(d) as compliant with trade rules and not arbitrary, finding that salt forms with modest improvements did not meet the standard of invention required for patents. The court also found it had jurisdiction to review compliance of domestic laws with international treaties.
This document discusses several patent cases in India between foreign pharmaceutical companies and Indian generic drug manufacturers. It summarizes key patent cases such as Novartis vs. India regarding Glivec, Bayer vs. Natco regarding Nexavar, Roche vs. Cipla regarding Tarceva. It also discusses India's patent laws including sections 3(d) and compulsory licensing. Many foreign drug patents were revoked by Indian courts based on lack of innovation or in the interest of public health and making medicines more affordable in India. The document supports India's stance on promoting generic competition and ensuring access to healthcare.
The document summarizes two key patent cases in India - Novartis AG's plea seeking patent protection for its cancer drug Glivec, which was dismissed, and Natco Pharma's compulsory license application for the cancer drug Nexavar, which was granted. The Novartis ruling confirmed that slight modifications alone do not warrant patents under Indian law. The Nexavar ruling allowed Natco to sell cheaper copies of Nexavar, requiring it to pay Bayer royalties and supply some free doses annually. These rulings make life-saving drugs more affordable in India by allowing generics, though multinational companies argue they could reduce pharmaceutical investment and innovation.
The document provides an overview of pharmaceutical patenting in India. It discusses key topics such as the role of intellectual property rights (IPRs) like patents, trademarks, and trade secrets in the pharmaceutical industry. It also examines India's pharmaceutical industry evolution from pre-independence to present. Specific issues covered include requirements for patentability, types of pharmaceutical patents, Section 3(d) of the Indian Patents Act, evergreening practices, compulsory licensing provisions, and mail box applications. The document uses examples like the Novartis case related to Gleevec and Natco Pharma's compulsory license for Bayer's anti-cancer drug Nexavar to illustrate relevant legal concepts and issues in Indian pharmaceutical patenting.
Ip protected invention in the field of biotechnologyKaran Veer Singh
This document discusses patenting of microorganisms, recombinant DNA, plant processes, gene patents, and applications of DNA sequences in India. Key points:
1) Isolated, mutated, adapted, and recombinant microorganisms can be patented under Indian law, and must be deposited in an IDA with disclosed source and geography.
2) Recombinant DNA techniques allow for patenting of processes, products, microorganisms and their variants, and proteins.
3) Plant processes involving increasing yield, genetic transformation, tissue culture, micropropagation, and somatic embryogenesis are patentable.
4) Gene patents can claim DNA sequences, proteins, recombinant plasmids, GM organisms, and production processes
The document discusses the patentability of microorganisms. It notes that prior to 1980, microorganisms were not considered patentable as they were natural products. However, in 1980 the Supreme Court ruled in the case of Chakrabarty v. General Electric that genetically modified microorganisms could be patented. The ruling established that microorganisms created through human manipulation with an industrial use could be patented. This opened the door for biotechnology to become a major industry. The document also discusses India's stance on patenting microorganisms and other biological materials.
This document discusses the patenting of life forms, including:
- The evolution of life form patenting in the US, allowing microorganisms, plants, animals, and human genes and cell lines to be patented.
- The patenting of life forms is also allowed in Europe and India with some limitations.
- There are pros and cons to patenting life forms - it can encourage research but also hinder it if it leads to monopolization of important genetic materials.
Patents and Biotechnology- A Presentation by Dr. Kalyan Kankanala - BananaIPBananaIP Counsels
Patents and Biotechnology- A Presentation by Dr. Kalyan Kankanala - BananaIP
BananaIP Counsels, formerly Brain League IP Services, founded in 2004 at the Indian Institute of Management (IIM) Bangalore’s incubation center (NSRCEL), is recognized as an IP/Patent trailblazer in India. The firm’s mission is to help clients maximize business value from their Intellectual Property (IP)/Patents, and gain competitive advantage in the market place. In its evolution from Brain League, BananaIP carries forward the firm’s core values – Merger of Technology,Management and Law, Swift Adaptation to changes in competitive environment, and business driven approach to Intellectual Property (IP)/Patent Services.
Contact Us for Intellectual Property Services
BananaIP Counsels
Regd Office
No.40,3rd Main Road,JC Industrial Estate,
Kanakapura Road,Bangalore – 560 062.
Email: contact@bananaip.com
Telephone: +91-80-26860414 /24/34
Genetically modified organisms (GMOs) can be engineered in several ways to alter plant traits. Some common applications include making crop plants resistant to herbicides, allowing farmers to spray fields without damaging crops. Corn, soybeans, and cotton in the US are often engineered for herbicide resistance. GMOs are also used to improve crop quality, increase nutrient levels, and produce pharmaceuticals and vaccines in plants. However, the ethics and impacts of GMO technology are debated, with concerns about environmental effects, corporate control of seeds and genes, and impacts on developing countries.
INTELLECTUAL PROPERTY RIGHTS IN BIOTECHNOLOGYNamitha M R
The document discusses various topics related to agricultural biotechnology and protection of biological resources. It provides definitions of agricultural biotechnology, lists its major benefits, and discusses economic implications. It also describes international agreements like the Convention on Biological Diversity, Cartagena Protocol, Nagoya Protocol, and International Treaty on Plant Genetic Resources. Biosafety procedures in India are outlined. Issues around IPR, trait-genetic use restriction technology, and India's national biodiversity protection initiatives are summarized as well. Current research status in biotechnology and some upcoming innovations are briefly mentioned.
Your IP Strategy & Patent Litigation Support Partner | Patent Research & Technology Intelligence Services| Patent Analysis Services
We help our medical device clients with technology intelligence services which is helpful to develop IP strategies. In addition, we provide research support to finalise the prototype of the Medical diagnostic kits. Over the years we have executed more than 100+ intellectual property research and analysis projects in the medical diagnostic domain.
Generally after analysing the patent results the decision makers are able to understand the market dynamics.
The document provides an overview of intellectual property laws and conventions related to plant varieties, biodiversity, and genetic resources in India. It discusses the Patents Act of 1970 and exceptions to patentability. It introduces the plant variety protection system including the International Union for the Protection of New Varieties of Plants (UPOV) and India's Protection of Plant Varieties and Farmers' Rights (PPV&FR) Act of 2001. The PPV&FR Act provides for the registration of new plant varieties, protection of breeders' and farmers' rights, and benefit sharing. The document also mentions international agreements like the Convention on Biological Diversity and the International Treaty on Plant Genetic Resources for Food and Agriculture that govern access to
BIOTECHNOLOGY PATENTS – STATUS OF PROTECTIONChiragZala6
The document discusses biotechnology patents in India. It provides background on intellectual property rights in biotechnology and how India's patent law was amended in 2002 to explicitly include biotechnology. Key points covered include what is and isn't patentable under Indian law for biotechnology, such as discoveries in nature not being patentable but purified biological materials produced through technical means can be. The legislative framework and policies governing biotechnology in India are also outlined.
The document discusses the evolution and growth of India's biotechnology sector. Some key points:
- India has emerged as a dominant player in biotechnology, growing at 30-35% annually and becoming the 12th largest destination globally.
- The sector has grown from a small beginning 25 years ago when the Department of Biotechnology was established, to over 400 companies today employing hundreds of thousands.
- Indian biotech companies have developed drugs for diseases like cancer and diabetes and produce vaccines at significantly lower costs than international markets.
- The government has strongly supported the sector through funding, institutions, and a supportive regulatory environment. However, the regulatory process remains complex.
- India has strengths in human resources
The document discusses various aspects of patenting and regulating natural products. It defines what a patent is and explains intellectual property rights. It provides examples of patents on natural products for new formulations, new uses of constituents, and modified natural compounds. It also discusses biopiracy and provides case studies on patents granted on turmeric and neem in other countries. Finally, it outlines WHO guidelines and recommendations for regulating herbal medicines in South East Asia.
Intellectual property rights (IPR) refer to the legal ownership of intellectual property such as inventions, literary works, symbols and designs. IPR is limited by duration, scope, and geography. The importance of IPR was first recognized in the Paris Convention of 1883 and Berne Convention of 1886, which are administered by the World Intellectual Property Organization (WIPO). IPR promotes innovation and creativity by granting time-limited ownership rights over intellectual commodities and creations of the mind.
This document provides an overview of the case of Natco Pharma Ltd. vs Bayer regarding the compulsory licensing of the cancer drug Nexavar in India. It discusses how Natco applied for and was granted a compulsory license to produce a generic version at a lower price after Bayer refused to provide a voluntary license or lower the price. The considerations for granting the license included that Bayer had not made the drug sufficiently available or affordable to meet patient needs in India. The verdict upheld the license with some conditions for Natco and increased the royalty rate. The effects may include more compulsory licenses and lower drug prices but potential impacts on innovation.
This document provides an overview of the case of Natco Pharma Ltd. vs Bayer regarding the granting of the first ever compulsory license for a pharmaceutical patent in India. It discusses the key considerations and timeline of the case, including Natco's application for a compulsory license to produce the cancer drug Nexavar at an affordable price after Bayer refused to provide a voluntary license or lower the price. The document summarizes the Indian Patent Act provisions for compulsory licensing and the IPAB verdict upholding the license grant with a slightly increased royalty rate for Natco. It also outlines some of the effects on access to medicines and potential solutions.
This document discusses biosafety regulations in food technology. It begins by defining food safety and safe food, then discusses reasons for concern about food safety such as changes in food habits and globalization of food trade. It outlines the need for regulations in the food supply chain and various initiatives taken at international level like Codex Alimentarius Commission established in 1962 to set food standards. The document then discusses India's food safety legislation, the Food Safety and Standards Authority of India (FSSAI) established under the Food Safety and Standards Act, 2006. It provides details on the objectives, functions, implementation structure, licensing requirements, and various regulations under FSSAI including standards for food products, food additives, contaminants and more.
PATENTING AND REGULATORY REQUIREMENTS OF NATURAL PRODUCTS
PROTECTION OF PLANT VARIETIES AND FARMERS' RIGHTS ACT, 2001
BIOPROSPECTING AND BIOPIRACY
PATENTING ASPECTS OF TRADITIONAL KNOWLEDGE AND NATURAL PRODUCTS. CASE STUDY OF
CURCUMA & NEEM
This document provides an overview of the conjunction between biotechnology and patent law, specifically regarding the patenting of living forms. It discusses how biotechnology inventions have become patentable subject matter under international agreements like TRIPS. It summarizes how Indian patent law was amended to comply with TRIPS, allowing for the patenting of biotechnological inventions involving genes, DNA sequences, and other living materials. The document outlines some of the debates around considering certain biotech discoveries as inventions that are eligible for patent protection.
The Biodiversity Act of 2002 was enacted to protect India's rich biodiversity and ensure equitable sharing of benefits from use of biological resources and traditional knowledge. Key aspects of the Act include regulating access to biological resources by foreigners, requiring approval from the National Biodiversity Authority for intellectual property rights involving Indian genetic material, establishing Biodiversity Management Committees to conserve biodiversity at the local level, and requiring benefit sharing for commercial use of resources. The Act aims to conserve biodiversity, ensure its sustainable use, and combat biopiracy of India's genetic wealth and traditional knowledge.
The document summarizes a seminar presentation on the role of plant quarantine in managing plant diseases in India. It discusses definitions of plant quarantine, types including domestic and national quarantine, objectives of plant quarantine in India such as preventing introduction of exotic pests and diseases. It also outlines the history and organizational structure of plant quarantine in India, procedures for import and export through plant quarantine, detection techniques used to identify pests and diseases, and measures taken to control spread of diseases.
GMP for Nutraceuticals...................Mayur Patil
GMP guidelines for nutraceuticals ensure product quality, safety, efficacy, and build consumer trust. Key components include quality management systems, facilities and equipment requirements, personnel qualifications, raw material standards, production controls, documentation, and more. Regulations vary by region but generally address manufacturing, labeling, claims, and registration/approval processes. In India, nutraceuticals are regulated under FSSAI, in the EU under Regulation (EU) 2015/2283, and in the US as dietary supplements under FDA's Current Good Manufacturing Practice regulations.
The document discusses the patentability of microorganisms. It notes that prior to 1980, microorganisms were not considered patentable as they were natural products. However, in 1980 the Supreme Court ruled in the case of Chakrabarty v. General Electric that genetically modified microorganisms could be patented. The ruling established that microorganisms created through human manipulation with an industrial use could be patented. This opened the door for biotechnology to become a major industry. The document also discusses India's stance on patenting microorganisms and other biological materials.
This document discusses the patenting of life forms, including:
- The evolution of life form patenting in the US, allowing microorganisms, plants, animals, and human genes and cell lines to be patented.
- The patenting of life forms is also allowed in Europe and India with some limitations.
- There are pros and cons to patenting life forms - it can encourage research but also hinder it if it leads to monopolization of important genetic materials.
Patents and Biotechnology- A Presentation by Dr. Kalyan Kankanala - BananaIPBananaIP Counsels
Patents and Biotechnology- A Presentation by Dr. Kalyan Kankanala - BananaIP
BananaIP Counsels, formerly Brain League IP Services, founded in 2004 at the Indian Institute of Management (IIM) Bangalore’s incubation center (NSRCEL), is recognized as an IP/Patent trailblazer in India. The firm’s mission is to help clients maximize business value from their Intellectual Property (IP)/Patents, and gain competitive advantage in the market place. In its evolution from Brain League, BananaIP carries forward the firm’s core values – Merger of Technology,Management and Law, Swift Adaptation to changes in competitive environment, and business driven approach to Intellectual Property (IP)/Patent Services.
Contact Us for Intellectual Property Services
BananaIP Counsels
Regd Office
No.40,3rd Main Road,JC Industrial Estate,
Kanakapura Road,Bangalore – 560 062.
Email: contact@bananaip.com
Telephone: +91-80-26860414 /24/34
Genetically modified organisms (GMOs) can be engineered in several ways to alter plant traits. Some common applications include making crop plants resistant to herbicides, allowing farmers to spray fields without damaging crops. Corn, soybeans, and cotton in the US are often engineered for herbicide resistance. GMOs are also used to improve crop quality, increase nutrient levels, and produce pharmaceuticals and vaccines in plants. However, the ethics and impacts of GMO technology are debated, with concerns about environmental effects, corporate control of seeds and genes, and impacts on developing countries.
INTELLECTUAL PROPERTY RIGHTS IN BIOTECHNOLOGYNamitha M R
The document discusses various topics related to agricultural biotechnology and protection of biological resources. It provides definitions of agricultural biotechnology, lists its major benefits, and discusses economic implications. It also describes international agreements like the Convention on Biological Diversity, Cartagena Protocol, Nagoya Protocol, and International Treaty on Plant Genetic Resources. Biosafety procedures in India are outlined. Issues around IPR, trait-genetic use restriction technology, and India's national biodiversity protection initiatives are summarized as well. Current research status in biotechnology and some upcoming innovations are briefly mentioned.
Your IP Strategy & Patent Litigation Support Partner | Patent Research & Technology Intelligence Services| Patent Analysis Services
We help our medical device clients with technology intelligence services which is helpful to develop IP strategies. In addition, we provide research support to finalise the prototype of the Medical diagnostic kits. Over the years we have executed more than 100+ intellectual property research and analysis projects in the medical diagnostic domain.
Generally after analysing the patent results the decision makers are able to understand the market dynamics.
The document provides an overview of intellectual property laws and conventions related to plant varieties, biodiversity, and genetic resources in India. It discusses the Patents Act of 1970 and exceptions to patentability. It introduces the plant variety protection system including the International Union for the Protection of New Varieties of Plants (UPOV) and India's Protection of Plant Varieties and Farmers' Rights (PPV&FR) Act of 2001. The PPV&FR Act provides for the registration of new plant varieties, protection of breeders' and farmers' rights, and benefit sharing. The document also mentions international agreements like the Convention on Biological Diversity and the International Treaty on Plant Genetic Resources for Food and Agriculture that govern access to
BIOTECHNOLOGY PATENTS – STATUS OF PROTECTIONChiragZala6
The document discusses biotechnology patents in India. It provides background on intellectual property rights in biotechnology and how India's patent law was amended in 2002 to explicitly include biotechnology. Key points covered include what is and isn't patentable under Indian law for biotechnology, such as discoveries in nature not being patentable but purified biological materials produced through technical means can be. The legislative framework and policies governing biotechnology in India are also outlined.
The document discusses the evolution and growth of India's biotechnology sector. Some key points:
- India has emerged as a dominant player in biotechnology, growing at 30-35% annually and becoming the 12th largest destination globally.
- The sector has grown from a small beginning 25 years ago when the Department of Biotechnology was established, to over 400 companies today employing hundreds of thousands.
- Indian biotech companies have developed drugs for diseases like cancer and diabetes and produce vaccines at significantly lower costs than international markets.
- The government has strongly supported the sector through funding, institutions, and a supportive regulatory environment. However, the regulatory process remains complex.
- India has strengths in human resources
The document discusses various aspects of patenting and regulating natural products. It defines what a patent is and explains intellectual property rights. It provides examples of patents on natural products for new formulations, new uses of constituents, and modified natural compounds. It also discusses biopiracy and provides case studies on patents granted on turmeric and neem in other countries. Finally, it outlines WHO guidelines and recommendations for regulating herbal medicines in South East Asia.
Intellectual property rights (IPR) refer to the legal ownership of intellectual property such as inventions, literary works, symbols and designs. IPR is limited by duration, scope, and geography. The importance of IPR was first recognized in the Paris Convention of 1883 and Berne Convention of 1886, which are administered by the World Intellectual Property Organization (WIPO). IPR promotes innovation and creativity by granting time-limited ownership rights over intellectual commodities and creations of the mind.
This document provides an overview of the case of Natco Pharma Ltd. vs Bayer regarding the compulsory licensing of the cancer drug Nexavar in India. It discusses how Natco applied for and was granted a compulsory license to produce a generic version at a lower price after Bayer refused to provide a voluntary license or lower the price. The considerations for granting the license included that Bayer had not made the drug sufficiently available or affordable to meet patient needs in India. The verdict upheld the license with some conditions for Natco and increased the royalty rate. The effects may include more compulsory licenses and lower drug prices but potential impacts on innovation.
This document provides an overview of the case of Natco Pharma Ltd. vs Bayer regarding the granting of the first ever compulsory license for a pharmaceutical patent in India. It discusses the key considerations and timeline of the case, including Natco's application for a compulsory license to produce the cancer drug Nexavar at an affordable price after Bayer refused to provide a voluntary license or lower the price. The document summarizes the Indian Patent Act provisions for compulsory licensing and the IPAB verdict upholding the license grant with a slightly increased royalty rate for Natco. It also outlines some of the effects on access to medicines and potential solutions.
This document discusses biosafety regulations in food technology. It begins by defining food safety and safe food, then discusses reasons for concern about food safety such as changes in food habits and globalization of food trade. It outlines the need for regulations in the food supply chain and various initiatives taken at international level like Codex Alimentarius Commission established in 1962 to set food standards. The document then discusses India's food safety legislation, the Food Safety and Standards Authority of India (FSSAI) established under the Food Safety and Standards Act, 2006. It provides details on the objectives, functions, implementation structure, licensing requirements, and various regulations under FSSAI including standards for food products, food additives, contaminants and more.
PATENTING AND REGULATORY REQUIREMENTS OF NATURAL PRODUCTS
PROTECTION OF PLANT VARIETIES AND FARMERS' RIGHTS ACT, 2001
BIOPROSPECTING AND BIOPIRACY
PATENTING ASPECTS OF TRADITIONAL KNOWLEDGE AND NATURAL PRODUCTS. CASE STUDY OF
CURCUMA & NEEM
This document provides an overview of the conjunction between biotechnology and patent law, specifically regarding the patenting of living forms. It discusses how biotechnology inventions have become patentable subject matter under international agreements like TRIPS. It summarizes how Indian patent law was amended to comply with TRIPS, allowing for the patenting of biotechnological inventions involving genes, DNA sequences, and other living materials. The document outlines some of the debates around considering certain biotech discoveries as inventions that are eligible for patent protection.
The Biodiversity Act of 2002 was enacted to protect India's rich biodiversity and ensure equitable sharing of benefits from use of biological resources and traditional knowledge. Key aspects of the Act include regulating access to biological resources by foreigners, requiring approval from the National Biodiversity Authority for intellectual property rights involving Indian genetic material, establishing Biodiversity Management Committees to conserve biodiversity at the local level, and requiring benefit sharing for commercial use of resources. The Act aims to conserve biodiversity, ensure its sustainable use, and combat biopiracy of India's genetic wealth and traditional knowledge.
The document summarizes a seminar presentation on the role of plant quarantine in managing plant diseases in India. It discusses definitions of plant quarantine, types including domestic and national quarantine, objectives of plant quarantine in India such as preventing introduction of exotic pests and diseases. It also outlines the history and organizational structure of plant quarantine in India, procedures for import and export through plant quarantine, detection techniques used to identify pests and diseases, and measures taken to control spread of diseases.
GMP for Nutraceuticals...................Mayur Patil
GMP guidelines for nutraceuticals ensure product quality, safety, efficacy, and build consumer trust. Key components include quality management systems, facilities and equipment requirements, personnel qualifications, raw material standards, production controls, documentation, and more. Regulations vary by region but generally address manufacturing, labeling, claims, and registration/approval processes. In India, nutraceuticals are regulated under FSSAI, in the EU under Regulation (EU) 2015/2283, and in the US as dietary supplements under FDA's Current Good Manufacturing Practice regulations.
The document provides guidelines for examination of patent applications in the field of pharmaceuticals in India. It discusses the historical development of pharmaceutical patenting in India and key provisions of Indian patent law. It covers assessment of inventions, novelty, inventive step, industrial applicability, non-patentable subject matter, and sufficiency of disclosure and claims. The guidelines are intended to help patent examiners achieve consistent examination standards and introduce harmonious practice.
Dr. Ravi Dhar reviews "IP Barriers in Generic Vaccines in 2014" Dr. Ravi Dhar
An overview of Intellectual Property Barriers in Generic Vaccines & how to circumvent these. Issues of affordability in tough Patent regime has also been mentioned.
Indian patent act - 1970 - definitions, history, types, terms, inventions patentable and non-patentable, patent filling procedure, rights of a patentee, offences and penalties.
Requesting a complete biosensor system in phyto-sourced drug discovery and de...iosrphr_editor
The IOSR Journal of Pharmacy (IOSRPHR) is an open access online & offline peer reviewed international journal, which publishes innovative research papers, reviews, mini-reviews, short communications and notes dealing with Pharmaceutical Sciences( Pharmaceutical Technology, Pharmaceutics, Biopharmaceutics, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy & Phytochemistry, Pharmacology, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest........more details on Aim & Scope).
Similar to Probiotics patenting trends in india (20)
The Department of Industrial Policy and Promotion (DIPP) recently notified amended Trademark Rules in 2017. The amended rules seek to simplify the trademark filing and prosecution process. Key changes include significant increases in official fees for trademark applications, renewals, and other filings. The rules also allow for online filing with a 10% discount on fees, hearings by video conference, and considering emails a valid form of document service.
The document discusses geographical indication (GI) registrations in India. It provides information on the GI registration process, including requirements for applications. It analyzes trends in registered GIs, finding that handicrafts dominate while the southern state of Karnataka has the most registrations. The document also introduces Intellocopia, an IP services firm that assists with acquiring, managing, and enforcing intellectual property rights.
To know the trends in patent filing in India in the field of Surgical Instruments, a detailed search was performed at the official website for the granted patents and the published applications. Presented here is the summary of the trends.
This document summarizes recent developments in patent and trademark prosecution in India. It outlines new guidelines published on examining biotechnology and computer-related invention patents. It also describes the Indian Patent Office beginning to process international applications and the launch of e-filing services for patents and trademarks. Statistics are provided on appeals data to the IPAB for patents and trademarks. The document was produced by Intellocopia, an Indian intellectual property services firm.
This document discusses Section 3(d) of the Indian Patents Act and its impact on the Indian pharmaceutical industry. It summarizes the key arguments made in a report by the US-India Business Council calling for the abolition of Section 3(d). The document analyzes the history of patent law in India and the rationale for including Section 3(d). It argues that Section 3(d) does not prevent incremental innovation or violate international agreements. Removing it could delay the introduction of cheaper generic drugs and harm public health. Overall, the document concludes that Section 3(d) is an important public health safeguard and that incentives should focus on research for diseases prevalent in emerging markets like India rather than removing the section.
The document discusses the evolution of intellectual property compliance and harmonization in India over time. It notes that various groups like patent offices, advocates, and IP attorneys need to continuously evolve, comply with international standards, and work towards harmonization. The document provides examples of patent cases where Indian decisions have aligned with international precedents. It also summarizes the services of Intellocopia IP Services in assisting with various IP needs.
The document outlines reforms to India's intellectual property regime in 2012, including increasing patent examiners, enabling online patent filing, issuing compulsory licenses, and publishing examination guidelines. It also discusses trademark reforms such as decentralizing trademark registry work and establishing an online tool for correcting errors. The presentation is the personal opinion of the author and intends to highlight important 2012 reforms.
Heritage Conservation.Strategies and Options for Preserving India HeritageJIT KUMAR GUPTA
Presentation looks at the role , relevance and importance of built and natural heritage, issues faced by heritage in the Indian context and options which can be leveraged to preserve and conserve the heritage.It also lists the challenges faced by the heritage due to rapid urbanisation, land speculation and commercialisation in the urban areas. In addition, ppt lays down the roadmap for the preservation, conservation and making value addition to the available heritage by making it integral part of the planning , designing and management of the human settlements.
2. 10 April 20142
Probiotics are Live microorganisms which when administered
in adequate amounts confer a health benefit on the host.
Probiotics have been shown to have beneficial effects against
various diseases and disorders, most common are:
• Gastrointestinal disorders
• Allergies- Skin, respiratory, food
• Cardiovascular diseases
• Metabolic disorders like Diabetes
• Obesity and overweight
• Urinogenital infections
• Kidney disorders
• Neurological disorders. www.freefromsupplements.com
3. 10 April 20143
Inventions in the field of probiotics include
Method for isolating/extracting/conditioning/modifying
live micro-organisms including various strains of bacteria
and yeast
New strains of bacteria and yeast
Compositions/formulations/products comprising micro-
organisms
Use of probiotics
4. 10 April 20144
The relevant sections of the Patent Act applicable for
ascertaining patentability of probiotic related invention are:
Section 3(c): the mere discovery of a scientific principle
or the formulation of an abstract theory or discovery of
any living thing or non-living substance occurring in
nature.
5. 10 April 20145
Section 3(d): the mere discovery of a new form of a
known substance, which does not result in the
enhancement of the known efficacy of that substance or
the mere discovery of any new property or new use for a
known substance or mere use of a known process,
machine or apparatus unless such known process results in
a new product or employs at least one new reactant.
6. 10 April 20146
Section 3(i): any process for the medicinal, surgical,
curative, prophylactic [diagnostic, therapeutic] or other
treatment of human beings or any process for a similar
treatment of animals to render them free of disease or to
increase their economic value or that of their products;
7. 10 April 20147
Section 3(j):plants and animals in whole or any part
thereof other than micro organisms but including seeds,
varieties and species and essentially biological processes
for production or propagation of plants and animals;
Section 3(p): an invention which, in effect, is traditional
knowledge of which is an aggregation or duplication of
known properties of additionally known component or
components.
9. 10 April 20149
Applicable international classes(IPC) for probiotic related
Inventions :
A23C A23L A23K A47G
A61K A61L A61M A61P
Other related classes :
C12N C12P C12Q C12R
10. 10 April 201410
Data Base Searched: Indian Patent Office
Time span: From 01.01.2002 to 01.03.2014
Patents searched were normalized manually for devices
for delivering probiotics and probiotics as animal feed.
Note: PCT applications which have designated India but
have not entered National phase are not included.
15. 10 April 201415
New microbial strains
Probiotic formulations for preventing /treating various
diseases
Probiotic compositions as targeted drug delivery system
Fortification of food stuffs with probiotics
eg: corn, soyabean, coffee beans
Kits for administering probiotics
16. 10 April 201416
Probiotic is still an underexplored field in India.
Total number of patents granted in the field of probiotics
are 42 and total number of published applications are 207.
A major portion of patents granted and published patent
application are national phase applications.
Nestec S. A.,the global leader in patent filing, continues to
dominate the Indian patent filing.
In India the government funded research establisment
CSIR, leads the patent filing.
17. 10 April 201417
Applicants should ascertain, that the subject matter in
respect of which a patent is sought, does not fall under
the exclusions mentioned in The Patent Act.
Deposition of the microorganism isolated/ conditioned/
extracted/modified should be at MTCC Chandigarh or
Pune.
Applicants are advised to follow guidelines for
examination of Biotechnology applications for patents
released by Indian Patent Office.
18. 10 April 201418
VIEWS EXPRESSED AND ERRORS, IF ANY ARE ATTRIBUTABLE TO
THE AUTHOR –
IF YOU RELY ON THE ABOVE VIEWS WITHOUT A PERSONALIZED
OPINION, AND IF YOU HAVE BENEFITS, YOU ARE FREE KEEP IT
FOR YOURSELF WITHOUT EVEN AN ACKNOWLEDGEMENT !!
IF YOU RELY ON THE ABOVE VIEWS, SOME OF IT MAY BE WRONG
AND SUFFER LOSES AND YOU SUE ME FOR NEGLIGENCE, I
RESERVE not only MY RIGHTS TO RECOVER COSTS(!) but also
raise new bill on you for relying upon these views!!
This presentation is primary meant for instructional use. Not for
Publication. The ownership of the TM & copyrighted material
(especially cartoons) appearing in the presentation is
acknowledged. Thanks to the Cartoonists, a dull presentation
receives an interesting touch.
19. 10 April 201419
Regd Off:- Office At:-
29, ‘SHESHASRI’, I ‘C’ CROSS, 890/4/5, 3rd A Main, D Block,
SN LAYOUT, BASAVESWARNAGAR, RAJAJINAGAR 2NDSTAGE,
BANGALORE-560079. BANGALORE-560010.
PH: 91-80-2352 1978 Cell: +91-94480 85810
URL: www.ipcopia.com e-mail: bhatta@ipcopia.com